Belinostat, the third approved HDAC inhibitor, is used in peripheral T cell lymphoma (PTCL) treatment, while Panobinostat was the fourth HDAC inhibitor approved for treating multiple myeloma. This evidence concerns the gene HDAC9 and plasma cell myeloma.